© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Alexa Fiffick, DO, MBS, MSCP
Articles
Educating Patients and Providers: Key Takeaways for Better VMS Management
March 28, 2025
Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.
Understanding the Link Between Elinzanetant and Somnolence
March 28, 2025
Panelists discuss how there is no change in therapeutic indication based on this particular finding, though it may serve as a beneficial side effect for patients struggling with sleep difficulties.
Long-Term Safety of New VMS Agents: What We Know So Far
March 28, 2025
Panelists discuss how long-term safety data for fezolinetant and elinzanetant remain unavailable, though short-term results show very positive outcomes with significantly higher efficacy than previous treatment options.
Liver Safety and Monitoring in VMS Treatment
March 28, 2025
Panelists discuss how fezolinetant and elinzanetant can cause liver-related adverse events requiring careful monitoring for drug-induced liver injury, noting that patients typically recover after discontinuation and emphasizing that primary providers are ideally positioned to manage patients with complex comorbidities.
How Primary Providers Can Prevent the Broader Health Impacts of VMS
March 28, 2025
Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).
Breaking Down the Science: Mechanisms of Action for New VMS Therapies
March 28, 2025
Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).
Beyond Hormone Therapy: Effective Alternatives for Managing Menopausal Symptoms
March 28, 2025
Panelists discuss how previous therapies lacked efficacy for vasomotor symptoms, while new treatments fezolinetant and elinzanetant offer superior effectiveness, with elinzanetant specifically addressing additional symptoms beyond the primary condition.
Understanding VMS in Menopause: Prevalence and Impact
March 28, 2025
Panelists discuss how vasomotor symptoms (VMS) can persist for years with variable manifestations, significantly disrupting both social and professional spheres, resulting in multibillion-dollar economic losses through decreased productivity and increased insurance costs.